Alicia Olivo Biography and Net Worth

Executive Vice President, General Counsel & Business Development of NeoGenomics


Ali has been serving as General Counsel since mid-April 2022. She has more than 14 years of corporate and legal expertise. She has been with NeoGenomics for over 5 years, representing the company in its acquisition of Inivata and Trapelo Health, as well as fundraising and governance activities. At NeoGenomics, she has also represented the company in various regulatory matters, including before the College of American Pathologists (CAP), the Office for Civil Rights (OCR), and the Office of Inspector General (OIG).

Prior to joining NeoGenomics, Ali served as a Director at PricewaterhouseCoopers, LLP, negotiating incentives for numerous Fortune 500 clients. She also spent many years at General Electric in various roles increasing in scope and responsibility, including Counsel, where she oversaw incentives negotiations, tax controversy, and government affairs.

What is Alicia C. Olivo's net worth?

The estimated net worth of Alicia C. Olivo is at least $368,319.68 as of November 15th, 2024. Ms. Olivo owns 37,129 shares of NeoGenomics stock worth more than $368,320 as of April 22nd. This net worth evaluation does not reflect any other assets that Ms. Olivo may own. Learn More about Alicia C. Olivo's net worth.

How old is Alicia C. Olivo?

Ms. Olivo is currently 40 years old. There are 6 older executives and no younger executives at NeoGenomics. The oldest executive at NeoGenomics is Mr. Christopher Michael Smith BSc, CEO & Director, who is 61 years old. Learn More on Alicia C. Olivo's age.

How do I contact Alicia C. Olivo?

The corporate mailing address for Ms. Olivo and other NeoGenomics executives is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. NeoGenomics can also be reached via phone at (239) 768-0600 and via email at sjones@neogenomics.com. Learn More on Alicia C. Olivo's contact information.

Has Alicia C. Olivo been buying or selling shares of NeoGenomics?

Alicia C. Olivo has not been actively trading shares of NeoGenomics in the last ninety days. Most recently, Alicia C. Olivo sold 5,175 shares of the business's stock in a transaction on Friday, November 15th. The shares were sold at an average price of $15.36, for a transaction totalling $79,488.00. Following the completion of the sale, the general counsel now directly owns 37,129 shares of the company's stock, valued at $570,301.44. Learn More on Alicia C. Olivo's trading history.

Who are NeoGenomics' active insiders?

NeoGenomics' insider roster includes (), Douglas Brown (Insider), George Cardoza (Insider), Bruce Crowther (Director), Mark Mallon (CEO), Kathryn McKenzie (CFO), Alicia Olivo (Executive Vice President, General Counsel & Business Development), and Robert Shovlin (Insider). Learn More on NeoGenomics' active insiders.

Are insiders buying or selling shares of NeoGenomics?

During the last year, insiders at the medical research company sold shares 1 times. They sold a total of 5,175 shares worth more than $79,488.00. The most recent insider tranaction occured on November, 15th when General Counsel Alicia C Olivo sold 5,175 shares worth more than $79,488.00. Insiders at NeoGenomics own 1.3% of the company. Learn More about insider trades at NeoGenomics.

Information on this page was last updated on 11/15/2024.

Alicia C. Olivo Insider Trading History at NeoGenomics

See Full Table

Alicia C. Olivo Buying and Selling Activity at NeoGenomics

This chart shows Alicia C Olivo's buying and selling at NeoGenomics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$50k$0$50kTotal Insider BuyingTotal Insider Selling

NeoGenomics Company Overview

NeoGenomics logo
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Read More

Today's Range

Now: $9.74
Low: $9.57
High: $10.06

50 Day Range

MA: $10.10
Low: $8.20
High: $14.42

2 Week Range

Now: $9.74
Low: $8.05
High: $19.12

Volume

1,099,197 shs

Average Volume

955,452 shs

Market Capitalization

$1.25 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.41